Literature DB >> 1400730

Determination of lansoprazole and its metabolites in plasma by high-performance liquid chromatography using a loop column.

B D Landes1, G Miscoria, B Flouvat.   

Abstract

A high-performance liquid chromatographic method for the simultaneous determination of lansoprazole, a new proton pump inhibitor, and its metabolites in human plasma is described. Lansoprazole, its metabolites and an internal standard were extracted with tert.-butyl methyl ether. Samples were injected using an automatic injector via a loop column, and separation was obtained using a reversed-phase column under isocratic conditions. The absorbance was monitored at 285 and 303 nm. The quantification limit was 2 ng/ml for lansoprazole and 3 or 5 ng/ml for the metabolites. No endogenous compounds were found to interfere. The mean overall recovery was between 75 and 95% for lansoprazole and its metabolites. This method is suitable for pharmacokinetic studies.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1400730     DOI: 10.1016/0378-4347(92)80605-p

Source DB:  PubMed          Journal:  J Chromatogr


  8 in total

1.  Single and multiple dose pharmacokinetics of lansoprazole in elderly subjects.

Authors:  B Flouvat; B Delhotal-Landes; A Cournot; F Dellatolas
Journal:  Br J Clin Pharmacol       Date:  1993-11       Impact factor: 4.335

2.  Pharmacokinetics of lansoprazole in patients with renal or liver disease of varying severity.

Authors:  B Delhotal-Landes; B Flouvat; J Duchier; P Molinie; F Dellatolas; M Lemaire
Journal:  Eur J Clin Pharmacol       Date:  1993       Impact factor: 2.953

3.  Determination of lansoprazole in biological fluids and pharmaceutical dosage by HPLC.

Authors:  A Avgerinos; T h Karidas; C Potsides; S Axarlis
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1998 Apr-Jun       Impact factor: 2.441

4.  Effects of clarithromycin on lansoprazole pharmacokinetics between CYP2C19 genotypes.

Authors:  Masato Saito; Norio Yasui-Furukori; Tsukasa Uno; Takenori Takahata; Kazunobu Sugawara; Akihiro Munakata; Tomonori Tateishi
Journal:  Br J Clin Pharmacol       Date:  2005-03       Impact factor: 4.335

Review 5.  Lansoprazole. A review of its pharmacodynamic and pharmacokinetic properties and its therapeutic efficacy in acid-related disorders.

Authors:  L B Barradell; D Faulds; D McTavish
Journal:  Drugs       Date:  1992-08       Impact factor: 9.546

6.  Lansoprazole does not affect the bioavailability of oral contraceptives.

Authors:  W Fuchs; R Sennewald; U Klotz
Journal:  Br J Clin Pharmacol       Date:  1994-10       Impact factor: 4.335

Review 7.  Clinical pharmacokinetics of lansoprazole.

Authors:  B D Landes; J P Petite; B Flouvat
Journal:  Clin Pharmacokinet       Date:  1995-06       Impact factor: 6.447

8.  Spectrophotometric determination of certain benzimidazole proton pump inhibitors.

Authors:  A A Syed; Ayesha Syeda
Journal:  Indian J Pharm Sci       Date:  2008 Jul-Aug       Impact factor: 0.975

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.